COVID-19 treatment Remdesivir will cost thousands of dollars in the United States as confirmed by its maker, Gilead Sciences Incorporated. According to Bloomberg's latest report, the U.S. government and other developed countries will be charged $390 per vial of remdesivir, which is a total cost of $2,340 for a typical 5-day course of treatment.
Also Read: [COVID-19 Update] Coronavirus Led to Unprecedented Surge in Alzheimer's Fatalities
"We should have sufficient supply ... but we have to make sure it's in the right place at the right time," said O'Day.
It was also reported that Gilead is allowing generic makers to supply the drug in 127 poor or middle-income countries, with two of them already doing it for around $600 per treatment course. The report stated that the cost of remdesivir had been highly anticipated since it became the first medicine to show benefit during the ongoing novel coronavirus pandemic, which killed more than half a million people around the world in just six months.
Remdesivir was said it would be cost-effective in a range of $4,580 to $5,080 if it saved lives, as stated by the Institute for Clinical and Economic Review. This nonprofit group analyzes prices for other drugs or medicines.
